NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

I agree Doc logic. It’s all about Footnote 3. If you take a close look at the sentence on page 2, that Footnote 3 is in reference to:

and the Company is in the final stages of preparing an application for regulatory approval of DCVax®-L (¶47.)3

Then take a close look at what is included in Footnote 3:

3 See also https://www.sec.gov/ix?doc=/Archives/edgar/data/1072379/000141057823001633/nwbo20230630x10q.htm (last visited on August 24, 2023). Notably, Ray Tancredi, Divisional Vice President of Walgreens in charge of specialty pharmacy development and brand Rx/vaccine purchasing, recently noted in a presentation at the Asembia 2023 Specialty Pharmacy Summit that he anticipated DCVax®-L was in the pipeline to receive FDA approval in the near term. https://www.ajmc.com/view/an-overview-of-thespecialty-therapy-pipeline-in-2023.(last visited on August 24, 2023)

Then, ask yourself the following questions, and then honestly answer these questions:

(1) Where did Laura Posner get the information contained in Footnote 3 from? Did she come up with Footnote 3 on her own, or was this supplied by NWBio?

(2) Would Laura Posner include Footnote 3 in the response to the MTD, if NWBio was not going to file for DCVax-L regulatory approval with the FDA in the near-term?

(3) Would NWBio allow Laura Posner to include Footnote 3 in the response, if they are not planning to file for DCVax-L regulatory approval with the FDA in the near-term?